tetano
Editor, Senior Moderator
Infect Drug Resist
. 2021 Dec 10;14:5287-5291.
doi: 10.2147/IDR.S330743. eCollection 2021.
Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
Yonghao Xu[SUP] #[/SUP][SUP] 1 [/SUP], Manshu Li[SUP] #[/SUP][SUP] 1 [/SUP], Liang Zhou[SUP] #[/SUP][SUP] 1 [/SUP], Dongdong Liu[SUP] 1 [/SUP], Weiqun He[SUP] 1 [/SUP], Weibo Liang[SUP] 1 [/SUP], Qingwen Sun[SUP] 1 [/SUP], Huadong Sun[SUP] 1 [/SUP], Yimin Li[SUP] 1 [/SUP], Xiaoqing Liu[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has spread all over the world resulting in high mortality, yet no specific antiviral treatment has been recommended.
Methods: A retrospective descriptive study was conducted involving 19 consecutive critically ill patients during January 27, 2020 to April 18, 2020. Ribavirin was given at 0.15g q8h orally upon ICU admission for 7 to 21 days. Here, 28-day mortality, lower respiratory tract specimens (ETA), and ribavirin side effect on the day of ICU admission (Day 1), Day 7, Day 14 and Day 21 were analyzed.
Results: All the nineteen critically ill COVID-19 patients (14 males and 5 females, median age 56yr) survived through to the 28th day of observations with 6 patients (31.58%) being discharged from the ICU. The SARS-CoV-2 viral positivity in sputum/ETA was 100% (19/19) on Day 1, 73.68% (14/19) on Day 7, 57.89% (11/19) on Day 14 and 36.84% (7/19) on Day 21. Ribavirin side effect was not observed in these patients.
Conclusion: Ribavirin is well tolerated in critically ill patients with COVID-19 and may benefit COVID-19 patients through increasing the virus clearance.
Keywords: COVID-19; SARS-CoV-2; antiviral; ribavirin.
. 2021 Dec 10;14:5287-5291.
doi: 10.2147/IDR.S330743. eCollection 2021.
Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
Yonghao Xu[SUP] #[/SUP][SUP] 1 [/SUP], Manshu Li[SUP] #[/SUP][SUP] 1 [/SUP], Liang Zhou[SUP] #[/SUP][SUP] 1 [/SUP], Dongdong Liu[SUP] 1 [/SUP], Weiqun He[SUP] 1 [/SUP], Weibo Liang[SUP] 1 [/SUP], Qingwen Sun[SUP] 1 [/SUP], Huadong Sun[SUP] 1 [/SUP], Yimin Li[SUP] 1 [/SUP], Xiaoqing Liu[SUP] 1 [/SUP]
Affiliations
- PMID: 34916812
- PMCID: PMC8672023
- DOI: 10.2147/IDR.S330743
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has spread all over the world resulting in high mortality, yet no specific antiviral treatment has been recommended.
Methods: A retrospective descriptive study was conducted involving 19 consecutive critically ill patients during January 27, 2020 to April 18, 2020. Ribavirin was given at 0.15g q8h orally upon ICU admission for 7 to 21 days. Here, 28-day mortality, lower respiratory tract specimens (ETA), and ribavirin side effect on the day of ICU admission (Day 1), Day 7, Day 14 and Day 21 were analyzed.
Results: All the nineteen critically ill COVID-19 patients (14 males and 5 females, median age 56yr) survived through to the 28th day of observations with 6 patients (31.58%) being discharged from the ICU. The SARS-CoV-2 viral positivity in sputum/ETA was 100% (19/19) on Day 1, 73.68% (14/19) on Day 7, 57.89% (11/19) on Day 14 and 36.84% (7/19) on Day 21. Ribavirin side effect was not observed in these patients.
Conclusion: Ribavirin is well tolerated in critically ill patients with COVID-19 and may benefit COVID-19 patients through increasing the virus clearance.
Keywords: COVID-19; SARS-CoV-2; antiviral; ribavirin.